miR-200c inhibits TGF-β-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer.

about

The Network of Non-coding RNAs in Cancer Drug Resistance SLC6A1-miR133a-CDX2 loop regulates SK-OV-3 ovarian cancer cell proliferation, migration and invasion

P2860

Q58694197-9558EEE5-F326-40C7-9954-8388FDE98260 Q58796642-E9F90199-C325-4BBA-BF3B-AEBA7F7261C2

P2860

miR-200c inhibits TGF-β-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer.

Item

http://www.wikidata.org/entity/Q48549971

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

miR-200c inhibits TGF-β-induce ...... B1 and ZEB2 in gastric cancer.

@en

miR-200c inhibits TGF-β-induce ...... B1 and ZEB2 in gastric cancer.

@nl

type

Item

label

miR-200c inhibits TGF-β-induce ...... B1 and ZEB2 in gastric cancer.

@en

miR-200c inhibits TGF-β-induce ...... B1 and ZEB2 in gastric cancer.

@nl

prefLabel

miR-200c inhibits TGF-β-induce ...... B1 and ZEB2 in gastric cancer.

@en

miR-200c inhibits TGF-β-induce ...... B1 and ZEB2 in gastric cancer.

@nl

P1476

miR-200c inhibits TGF-β-induce ...... B1 and ZEB2 in gastric cancer.

@en

P2093

Baoen Shan

http://www.w3.org/2001/XMLSchema#string

Jing Han

http://www.w3.org/2001/XMLSchema#string

Jing Zuo

http://www.w3.org/2001/XMLSchema#string

Lianmei Zhao

http://www.w3.org/2001/XMLSchema#string

Meixiang Sang

http://www.w3.org/2001/XMLSchema#string

Riyang Zhao

http://www.w3.org/2001/XMLSchema#string

Xian-De Liu

http://www.w3.org/2001/XMLSchema#string

Xinliang Zhou

http://www.w3.org/2001/XMLSchema#string

Xinyi Men

http://www.w3.org/2001/XMLSchema#string

Yalei Lv

http://www.w3.org/2001/XMLSchema#string

P2860

Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Global cancer statistics, 2012

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

The role of the miR-200 family in epithelial-mesenchymal transition.

Molecular profiling of tumour budding implicates TGFβ-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma.

Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population.

Targeting HER proteins in cancer therapy and the role of the non-target HER3.

Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer.

P2888

s41417-017-0005-y

P31

scholarly article

P356

10.1038/S41417-017-0005-Y

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29302045

http://www.w3.org/2001/XMLSchema#string

miR-200c inhibits TGF-β-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer.

about

P2860

P2860

miR-200c inhibits TGF-β-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P31

P356

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P31

P356

P577

P698